Table 1:
Clinicopatholgical characteristics of the patient cohorts
| In-silico discovery and validation | Clinical validation | ||||
|---|---|---|---|---|---|
| TCGA | ICGC | E-MTAB-6134 | GSE71729 | Cohort | |
| (n=163) | (n=95) | (n=288) | (n=143) | (n=119) | |
| Sex | |||||
| Men | 90 | 49 | 166 | 55 | 60 |
| Women | 73 | 46 | 122 | 67 | 59 |
| Age (years) | |||||
| Mean ± SD | 64.6 ± 11.1 | 66.5 ± 11.2 | NA | NA | 67.4 ± 10.5 |
| Histological type | |||||
| PDAC | 154 | 81 | 288 | NA | 119 |
| Neuroendocrine | 8 | 0 | 0 | NA | 0 |
| IPMC | 0 | 12 | 0 | NA | 0 |
| Acinar cell carcinoma | 0 | 2 | 0 | NA | 0 |
| Others/Not specified | 1 | 0 | 0 | NA | 0 |
| Location | |||||
| Head | 132 | 75 | NA | NA | 73 |
| Body | 13 | 5 | NA | NA | 27 |
| Tail | 15 | 15 | NA | NA | 9 |
| Others/Not specified | 0 | 0 | 10 | ||
| Differentiation | |||||
| Well | 29 | 1 | NA | 16 | 52 |
| Mod | 86 | 55 | NA | 49 | 47 |
| Poor | 45 | 34 | NA | 34 | 9 |
| Others/Not specified | 2 | 5 | NA | NA | 11 |
| T-stage | |||||
| Tis | 0 | NA | 0 | NA | 2 |
| T1 | 8 | NA | 12 | 2 | 14 |
| T2 | 19 | NA | 39 | 20 | 2 |
| T3 | 132 | NA | 237 | 91 | 84 |
| T4 | 3 | NA | 0 | 1 | 11 |
| N-stage | |||||
| N0 | 46 | NA | 72 | 36 | 43 |
| N1 | 115 | NA | 216 | 80 | 71 |
| NX | 1 | NA | 0 | NA | 0 |
| M-stage | |||||
| M0 | 159 | NA | NA | 115 | 111 |
| M1 | 3 | NA | NA | 2 | 7 |
| AJCC Stage | |||||
| 0 | 0 | 0 | NA | NA | 2 |
| IA | 7 | 4 | NA | NA | 11 |
| IB | 13 | 5 | NA | NA | 2 |
| IIA | 25 | 25 | NA | NA | 24 |
| IIB | 110 | 54 | NA | NA | 57 |
| III | 4 | 1 | NA | NA | 9 |
| IV | 3 | 6 | NA | NA | 7 |
| R- status | |||||
| R0 | 99 | NA | 235 | NA | 114 |
| R1 | 51 | NA | 49 | NA | 4 |
| R2 | 2 | NA | 0 | NA | 1 |
| RX | 4 | NA | 4 | NA | 0 |
Abbreviations: NA, Not Available; IPMC, Intra Papillary Mucinous Adenocarcinoma